The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ISTURISA (Recordati Rare Diseases Australia Pty Ltd)
Product name
ISTURISA
Date registered
Evaluation commenced
Decision date
Approval time
122 (255 working days)
Active ingredients
osilodrostat phosphate
Registration type
NCE/NBE
Indication
ISTURISA (film-coated tablet) is indicated for the treatment of endogenous Cushing's syndrome in adults.